Update from BP couple of wee snips "OPT-302 moves up in the...

Update from BP couple of wee snips

"OPT-302 moves up in the wet-AMD pecking order We expect Opthea with its drug OPT-302 to be a likely beneficiary of peer US based Opthotech’s setback on failure of its lead drug Fovista (anti-PDGF) in Phase 3 trials. Of the emerging wet-AMD therapies the anti-PDGF agents were garnering the most attention and were the most advanced. Fovista’s failure in the Phase 3 trials, coupled with the Phase 2 failure of Regeneron’s anti-VEGF/PDGF co-formulation rinucumab likely signals an end to the PDGF approach. This consequently moves OPT-302 up in the pecking order of drugs in development for wet AMD and therefore increases its attractiveness. OPT-302 which is targeting VEGF-C/D is now one of 2 potential combination targets with anti-VEGF in advanced development. We believe scarcity has value and as a consequence expect increased interest in the asset from the key players in the wet AMD market. "

and

"Valuation lifted by 16% to $0.95, Retain Buy "